American Bio Medica Corp. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
788.00
490.00
333.00
345.00
545.00
1,028
Depreciation, Depletion & Amortization
116.00
111.00
91.00
91.00
80.00
81
Other Funds
229.00
7.00
-
-
-
260
Funds from Operations
14.00
86.00
167.00
55.00
242.00
687
Changes in Working Capital
23.00
12.00
63.00
296.00
423.00
467
Net Operating Cash Flow
9.00
98.00
230.00
241.00
181.00
220
Capital Expenditures
34.00
75.00
21.00
30.00
64.00
Sale of Fixed Assets & Businesses
-
10.00
-
-
-
Net Investing Cash Flow
34.00
65.00
21.00
30.00
64.00
Issuance/Reduction of Debt, Net
811.00
320.00
403.00
213.00
237.00
Net Financing Cash Flow
582.00
327.00
403.00
213.00
237.00
Net Change in Cash
557.00
294.00
194.00
2.00
120.00
Free Cash Flow
5.00
47.00
217.00
241.00
137.00

About American Bio Medica

View Profile
Address
122 Smith Road
Kinderhook New York 12106
United States
Employees -
Website http://www.abmc.com
Updated 07/08/2019
American Bio Medica Corp. engages in the manufacture and sale of immunoassay tests, primarily for the immediate detection of certain drugs in urine and oral fluids. Its products includes Rapid Drug Screen, Rapid ONE, RDS InCup, Rapid TOX, Rapid TOX Cupp II, and OralStat. The company was founded by Stan Cipkowski and Edmund M.